Esophageal and Gastrointestinal Tumor Center, Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, China.
Anhui Province Key Laboratory of Medical Physics and Technology; Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China.
Front Immunol. 2024 Feb 19;15:1330785. doi: 10.3389/fimmu.2024.1330785. eCollection 2024.
Esophageal squamous cell carcinoma (ESCC) is the main prevalent histological subtype and accounts for 85% of esophageal cancer cases worldwide. Traditional treatment for ESCC involves chemotherapy, radiotherapy, and surgery. However, the overall prognosis remains unfavorable. Recently, immune checkpoint blockade (ICB) therapy using anti-programmed cell death-1 (PD-1)/PD-1 ligand (PD-L1) antibodies have not only achieved remarkable benefits in the clinical management of ESCC but have also completely changed the treatment approach for this cancer. In just a few years, ICB therapy has rapidly advanced and been added to standard first-line treatment regimen in patients with ESCC. However, preoperative immunotherapy is yet to be approved. In this review, we summarize the ICB antibodies commonly used in clinical immunotherapy of ESCC, and discuss the advances of immunotherapy combined with chemotherapy and radiotherapy in the perioperative treatment of ESCC, aiming to provide reference for clinical management of ESCC patients across the whole course of treatment.
食管鳞状细胞癌（ESCC）是主要的流行组织学亚型，占全球食管癌病例的 85%。ESCC 的传统治疗包括化疗、放疗和手术。然而，整体预后仍然不佳。最近，使用抗程序性细胞死亡蛋白-1（PD-1）/PD-1 配体（PD-L1）抗体的免疫检查点阻断（ICB）治疗不仅在 ESCC 的临床管理中取得了显著的疗效，而且还彻底改变了这种癌症的治疗方法。在短短几年内，ICB 治疗迅速发展，并被添加到 ESCC 患者的标准一线治疗方案中。然而，术前免疫疗法尚未得到批准。在这篇综述中，我们总结了常用于 ESCC 临床免疫治疗的 ICB 抗体，并讨论了免疫疗法与化疗和放疗联合在 ESCC 围手术期治疗中的进展，旨在为 ESCC 患者的整个治疗过程的临床管理提供参考。
